Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update

Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its schedule for the third quarter 2022 financial results and corporate update, set for November 9, 2022. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET.

The company focuses on developing therapeutics for viral diseases, including HBV and SARS-CoV-2. Notably, its lead compound AB-729 is undergoing evaluation in multiple phase 2 clinical trials.

Positive

• AB-729 is the only RNAi therapeutic with evidence of immune re-awakening in HBV.
• Ongoing phase 2 clinical trials for AB-729 indicate potential progress in HBV treatment.

Negative

• None.

WARMINSTER, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its third quarter 2022 financial results and corporate update for Wednesday, November 9, 2022. The schedule for the press release and conference call/webcast are as follows:

•	Q3/2022 Press Release:	Wednesday, November 9, 2022 at 7:30 a.m. ET
•	Q3/2022 Conference Call/Webcast:	Wednesday, November 9, 2022 at 8:45 a.m. ET

To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.  

An archived webcast will be available on the Arbutus website after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, we are developing a RNAi therapeutic, an oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that we intend to combine with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

FAQ

What is the date of Arbutus Biopharma's Q3 2022 financial results?

The Q3 2022 financial results will be released on November 9, 2022.

When will the conference call for Arbutus Biopharma's Q3 2022 results take place?

The conference call will take place on November 9, 2022, at 8:45 a.m. ET.

What is AB-729 being evaluated for?

AB-729 is being evaluated for its potential as a therapeutic for chronic Hepatitis B virus (HBV).